SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Syndesi Therapeutics Contact Information. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. If you qualify, please. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. Terms of use AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. In-Line Products . "I am delighted with the closing of this deal. To connect with Syndesi Therapeutics employee register on SignalHire. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. AbbVie Inc. said it's purchased a Belgian maker of neuroscience drugs in a deal that could be worth as much as $1 billion. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Syndesi Therapeutics AbbVie assumes no duty to update the information to reflect subsequent developments. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn. Their latest funding was raised on Sep 28, 2020 from a Series A round. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right . Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Regulating the synaptic transmission is a promising approach to treat Alzheimers disease and other disorders with cognitive impairment. Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Board. Get the latest business insights from Dun & Bradstreet. "I am delighted with the closing of this deal. Address: Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. AbbVie will pay Syndesi shareholders an upfront payment of $130m as part . Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. Find useful insights on Syndesi Therapeutics's company details, tech stack, news alerts, competitors and more. Synaptic dysfunction, with the consequent disruption of connectivity bet ween brain regions, underlies cognitive impairment seen in multiple CNS . UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. Active, Closed, Last funding round type (e.g. Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . - Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. The information in the press releases on these pages was factually accurate on the date of publication. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple CNS disorders, including Alzheimers Disease, schizophrenia and depresson. Syndesi Therapeutics is developing molecules which act in a unique way on the synaptic vesicle protein SV2A. Syndesi Therapeutics is funded by 9 investors. Syndesi Therapeutics General Information. The mechanism is currently being evaluated for . Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. View our social media channel guidelines , AbbVie.com The North Chicago-based pharmaceutical giant (NYSE: ABBV . The company's drugs can modulate the synaptic vesicl, eu fugiat nulla pariatur. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Developer of drug molecules designed to treat cognitive impairment. The company has also benefited from support from the Walloon Region. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Sign up Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Follow @abbvie on Twitter, Facebook, Instagram, YouTubeand LinkedIn. The mechanism is currently . "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," saidTom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Syndesi Therapeutics has exclusively licensed a first-in-class small molecule program from UCB and the series A investment totalling 17M will fund the clinical development of the lead compound up to early proof-of-concept in humans. Readers should not rely upon the information in these pages as current or accurate after their publication dates. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Site map Developer of drug molecules designed to treat cognitive impairment. Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Kevin de Comines Dipl. Country: Belgium. AbbVie Inc. on Tuesday said it acquired Belgian clinical-stage biotechnology company Syndesi Therapeutics SA for up to $1 billion in a deal that expands its neuroscience portfolio. Company. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). North Chicago, Illinois-based AbbVie announced Tuesday that it paid $130 million up front to acquire Syndesi Therapeutics. | The "Yes" link below will take you out of the AbbVie family of websites. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . For further information This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Syndesi Therapeutics serves customers worldwide. Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. The deal will allow AbbVie to access Syndesi's research into the potential treatment of cognitive impairment and other symptoms associated with neurodegenerative and neuropsychiatric disorders, including major depressive disorder and Alzheimer's disease. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Total funding of the company - $21.2M. Get the full list. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. 1348 Louvain-la-Neuve Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. The UK Life Sciences team advised Syndesi Therapeutics and its shareholders on Syndesi's acquisition by AbbVie (NYSE: ABBV). The deal will expand AbbVie 's neurological . AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. We are creating a new and unique treatment approach using differentiated bone-forming cells. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. These press releases remain on AbbVie's website for historical purposes only. Organization Website: syndesitherapeutics.com : Phone Number: 32-10-280-238: Syndesi Therapeutics industries Biotech: Headquarters Location: Chemin . Twyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing . The total value of the deal could rise . With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of . It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Copyright 2022 AbbVie Inc. North Chicago, Illinois, U.S.A. COPENHAGEN, Denmark, March 1, 2022 /PRNewswire/ -- Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ('Syndesi'). Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases. Phone Number +32 10 280 238. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. Launching Soon Launching Soon Launching Soon Launching Soon . "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases," said Jonathan Savidge, chief executive officer, Syndesi Therapeutics. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right therapy at their disposal. Novo Holdings and Fountain Healthcare Partners are the most recent investors. Milestone payments could bring shareholders of the biotech up to $870. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Published on March 6, 2022. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value radiopharmaceutical intellectual property, we are poised to deliver on the promise of . The deal will see AbbVie pay Syndesi shareholders a $130 million in an upfront payment with an additional $870 million available depending on if certain milestones are met. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. Before engaging, please read and adhere to our established community guidelines for each channel. Main article: Alzheimer's disease Syndesi Therapeutics is developing drugs to treat consistent cognitive disorders in various neurological conditions.. History 2022: AbbVie bought Syndesi Therapeutics for $1 billion. Products. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Personalize which data points you want to see and create visualizations instantly. Get the full list, Socit Rgionale d'Investissement de Wallonie, Youre viewing 5 of 8 investors. In addition to Syndesi Therapeutics Novo Seeds has launched four other companies in the neuroscience space including Muna Therapeutics (neurodegeneration), NMD Pharma (neuromuscular disorders), Hoba Therapeutics (Pain), and Avilex Pharma (Acute Ischemic Stroke). This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. Ut enim ad min, To view Syndesi Therapeuticss complete valuation and funding history, request access, To view Syndesi Therapeuticss complete cap table history, request access, Youre viewing 5 of 50 competitors. 2022 PitchBook. Westside Therapeutics Westside Therapeutics Westside Therapeutics. YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE. Find company research, competitor information, contact details & financial data for Syndesi Therapeutics of Ottignies-Louvain-la-Neuve, WALLOON BRABANT. View contacts for Syndesi Therapeutics to access new leads and connect with decision-makers. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. SV2A plays a central role in synaptic transmission (connections between neurons). Bone Therapeutics is an advanced biotechnology company with a unique approach to the development of cell therapy products for orthopaedics and bone diseases. We are harnessing science to improve connections on many levels. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help . Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission. Our name Syndesi comes from the Greek for connection. Syndesi Therapeutics offers modulators to improve cognition in diseases such as alzheimer's disease and other conditions causing cognitive impairment. On Mar 2, 2022. 17,000,000 Venture capital (Series A) FierceBiotech. More. Revenues for in-line products in the third quarter were $8.1 billion compared to $7.7 billion in the prior year period, representing an increase . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI 118. Ste.103. Resources. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). | Syndesi Therapeutics is actively using the technology Microsoft Exchange Online for its website, according to BuiltWith. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. For more information about AbbVie, please visit us atwww.abbvie.com. Use Slintel to connect with top decision-makers at Syndesi Therapeutics. About Syndesi Therapeutics . The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Company Type For Profit. 01 Mar 2022. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio. Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel to AbbVie. Syndesi Therapeutics. Jonathan Savidge Chief Executive Officer John Kemp Chief Scientific Officer Torsten Madsen Chief Medical Officer Maeve Duffy Head of Clinical Operations Steven Ramael Medical Director Jean Combalbert Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of . AbbVie, 01 March 2022: AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio.This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its . Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia, r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. The Syndesi Therapeutics annual revenue is estimated at < 1M. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Contact Email [email protected]. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. | Regulating synaptic transmission represents . On March 1, 2022, the American pharmaceutical giant AbbVie completed the acquisition of the Belgian biotechnology Syndesi Therapeutics. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. OM DAOM L.Ac. Belgium, the general policy of protection of personal data. For more information about AbbVie, please visit us atwww.abbvie.com. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. UCB spins out neuro startup with 17M from Novo, Johnson & Johnson Syndesi Therapeutics. Subscribe for email alerts When typing in this field, a list of search results will appear and be automatically updated as you type. "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases," said Jonathan Savidge, chief executive officer, Syndesi Therapeutics. About Syndesi Therapeutics. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". Under the terms of the agreement, AbbVie will pay Syndesi shareholders a $130 million upfront payment with the potential for Syndesi shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," said Tom Hudson . . | Funding Rounds Number of Funding Rounds 3 Total Funding Amount 26.2M AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Mar 01, 2022, 08:00 ET. Syndesi is investigating the potential of these molecules to improve cognition in diseases such as Alzheimer's Disease and other dementias, as well as other conditions such as major depression and cognitive impairment associated with schizophrenia. Privacy policy Syndesi Therapeutics has raised a total of 26.2M in funding over 3 rounds. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which. Place de lUniversit 16 bte 27 Cookie Settings. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. Solutions. Developer of drug molecules designed to treat cognitive impairment. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. There is a major unmet need for new therapies that can . San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Launching Soon Launching Soon Launching Soon Launching Soon . AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel . This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. This area is reserved for members of the news media. from 8 AM - 9 PM ET. Btiment Le Parc Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Win whats next. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease and related conditions. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. The mechanism is currently being evaluated . Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19.